AXL Inhibitor Compounds Selective Kinase Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current AXL inhibitors are inadequate in effectively targeting AXL-mediated diseases such as cancer, inflammation, and autoimmune disorders, with a need for more potent and selective compounds that can modulate AXL activity without significant side effects.
Innovation Solution
Development of novel compounds represented by Formula (I) and their pharmaceutically acceptable salts, hydrates, or solvates, which inhibit AXL activity, allowing for the treatment of various diseases and disorders mediated by AXL, including cancer, inflammation, and autoimmune disorders, with the potential for combination therapy with other agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current AXL inhibitors are used, then AXL activity is inhibited, but the inhibition is insufficient and side effects occur due to lack of selectivity
Solution Approach 1:
The patent applies local quality by designing a compound structure with specific functional groups positioned at precise locations to interact with unique residues in the AXL kinase domain. The compound features a heteroaryl amide portion that targets the ATP binding site and a substituted phenyl or heteroaryl group that forms specific interactions with AXL-specific residues, thereby achieving selective inhibition of AXL while sparing other RTKs.
Solution Approach 2:
The patent employs parameter changes by optimizing the chemical structure parameters of the inhibitor compounds, including the type of heteroaryl group, the position and nature of substituents, and the linkage between functional groups. These parameter optimizations enhance the compound's affinity for AXL and improve selectivity over other receptor tyrosine kinases, thereby increasing inhibition efficacy while reducing off-target effects.
2Reliability
If AXL inhibition is enhanced to treat cancer effectively, then therapeutic benefit increases, but selectivity over other receptor tyrosine kinases must be maintained to avoid side effects
Solution Approach 1:
The patent applies local quality by designing a compound structure with specific functional groups positioned at precise locations to interact with unique residues in the AXL kinase domain. The compound features a heteroaryl amide portion that targets the ATP binding site and a substituted phenyl or heteroaryl group that forms specific interactions with AXL-specific residues, thereby achieving selective inhibition of AXL while sparing other RTKs.
Solution Approach 2:
The patent uses the heteroaryl amide portion of the compound as an intermediary that bridges the substituent group and the core structure, enabling specific interactions with the AXL kinase domain. This intermediary functional group facilitates selective binding to AXL by forming hydrogen bonds and other interactions with key residues in the ATP binding site, thereby enhancing both potency and selectivity.
3Reliability
If new AXL inhibitor compounds are developed to improve efficacy, then inhibition potency increases, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor compound into distinct functional modules: a heteroaryl amide portion, a substituted phenyl or heteroaryl group, and linkage elements. This modular structure allows for systematic optimization of each component to enhance AXL binding affinity while maintaining a manageable level of overall molecular complexity that facilitates synthesis and characterization.
Data Source
AI summary
Compounds of Formula I that inhibit AXL, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by AXL.